Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › alteplase

alteplase

16 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of alteplase

11 trials tracked of alteplase: 8 in phase 3 or 4 and 6 with published results. The most-cited published study has 93 citations.

11Trials tracked
8Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 2 Phase 3 6 Phase 2 1 Other / NA 2
  1. Phase 3 Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS Completed · 93 cited
  2. Phase 3 A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity Completed · 90 cited
  3. Phase 3 Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III Completed · 62 cited
  4. Phase 4 Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endovascular System Completed · 36 cited
  5. Phase 3 Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset Completed · 17 cited
  6. Phase 3 Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase FORPE Completed · 4 cited
Show 5 more trials
  1. Phase 4 Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke （Japan Alteplase Clinical Trial Ⅱ：J-ACT Ⅱ） Completed
  2. Phase 3 Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic Stroke Completed
  3. Phase 2 Alteplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses Completed
  4. N/A SITS-IVT in Patients >80 Years Study Completed
  5. N/A Efficacy and Safety of Activase (Ateplase) vs Placebo in Complicated Pleural Effusions (CPE)/Empyemas Completed

Showing the 11 most-cited and recently-updated of 11 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Meta-analysis models cost-effectiveness of IV alteplase plus thrombectomy for large vessel occlusion stroke
Neurology Meta-analysis
Meta-analysis models cost-effectiveness of IV alteplase plus thrombectomy for large vessel occlusion stroke Adding alteplase to stroke surgery is cost-effective when treatment starts within 170 minutes
This meta-analysis models cost-effectiveness using individual patient data from 6 trials involving 2,268 patients across 16 countries.
Adding clot-busting medicine to stroke surgery saves money and improves value when treatment starts within 170 minutes, but benefits fade af…
Apr 19, 2026
Cortical Superficial Siderosis Burden Predicts Hemorrhage and Poor Outcomes After Stroke Thrombolysis
Neurology RCT
Cortical Superficial Siderosis Burden Predicts Hemorrhage and Poor Outcomes After Stroke Thrombolysis New Brain Scan Marker Predicts Bleeding Risk Before Treatment
A substudy of the AcT trial (alteplase versus tenecteplase) evaluated radiological Boston CAA criteria and constituent markers in 482 thromb…
A specific brain scan pattern predicts dangerous bleeding after clot-busting drugs, helping doctors decide who needs fast treatment to save …
Apr 15, 2026
Marked hyperglycemia linked to higher parenchymal hematoma risk with bridging therapy versus direct EVT in stroke
Neurology RCT
Marked hyperglycemia linked to higher parenchymal hematoma risk with bridging therapy versus direct EVT in stroke High blood sugar linked to bleeding risk after stroke clot removal procedure
A post hoc analysis of 627 patients from the DIRECT-MT trial found that in those with admission glucose >11.1 mmol/L, bridging therapy (alte…
Very high blood sugar levels may increase bleeding risk for stroke patients who receive clot-busting drugs before mechanical clot removal.
Apr 3, 2026
Reteplase and non-immunogenic staphylokinase show superior functional outcomes vs alteplase in AIS within 4.5h
Neurology Meta-analysis
Reteplase and non-immunogenic staphylokinase show superior functional outcomes vs alteplase in AIS within 4.5h Which clot-busting drug works best for stroke? Two newer options may help more people walk and talk normally again
A network meta-analysis of 21 RCTs (n=16,837) found reteplase (18+18 mg) and non-immunogenic recombinant staphylokinase (10 mg) were associa…
Two newer clot-busting drugs help more stroke patients walk and talk normally again without increasing the risk of dying within 90 days.
Frontiers Mar 30, 2026